Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance

被引:0
|
作者
Lukas Klameth
Barbara Rath
Maximilian Hochmaier
Doris Moser
Marlene Redl
Felicitas Mungenast
Katharina Gelles
Ernst Ulsperger
Robert Zeillinger
Gerhard Hamilton
机构
[1] Medical University of Vienna,Department of Pathophysiology and Allergy Research
[2] Medical University of Vienna,Deparment of Surgery
[3] Otto-Wagner Hospital,Respiratory Oncology Unit
[4] Medical University of Vienna,Department of Cranio
[5] Hospital Horn,Maxillofacial and Oral Surgery
[6] Medical University of Vienna,Department of Gynecology
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Small cell lung cancer (SCLC) represents 15% of lung cancers and is characterized by early dissemination, development of chemoresistance and a poor prognosis. A host of diverse drugs failed invariably and its mechanisms of global chemoresistance have not been characterized so far. SCLC represents the prototype of an aggressive and highly metastatic tumor which is ultimately refractory to any treatment. High numbers of circulating tumor cells (CTCs) allowed us to establish 5 CTC cell lines (BHGc7, 10, 16, 26 and UHGc5) from patients with recurrent SCLC. These cell lines exhibit the typical SCLC markers and CTCs of all patients developed spontaneously large multicellular aggregates, termed tumorospheres. Ki67 and carbonic anhydrase 9 (CAIX) staining of tumorosphere sections revealed quiescent and hypoxic cells, respectively. Accordingly, comparison of the chemosensitivity of CTC single cell suspensions with tumorospheres demonstrated increased resistance of the clusters against chemotherapeutics commonly used for treatment of SCLC. Therefore, global chemoresistance of relapsing SCLC seems to rely on formation of large tumorospheres which reveal limited accessibility, lower growth fraction and hypoxic conditions. Since similar tumor spheroids were found in other tumor types, SCLC seems to represent a unique tumor model to study the association of CTCs, metastasis and drug resistance.
引用
收藏
相关论文
共 50 条
  • [31] Chemoresistance factors in non-small cell lung cancer
    Shevchenko, A. I.
    Kolesnik, A. P.
    Kadzhoian, A. V.
    Kuzmenko, V. A.
    PATHOLOGIA, 2016, (01): : 4 - 9
  • [32] Circulating tumor DNA as a potential biomarker of radiographic tumor burden in small cell lung cancer
    Smith, Jarrod T.
    Balar, Aneri
    Lakhani, Dhairya A.
    Kluwe, Christien
    Zhao, Zhiguo
    Kopparapu, Prasad
    Almodovar, Karinna
    Muterspaugh, Anel
    Yan, Yingjun
    York, Sally
    Horn, Leora
    Antic, Sanja
    Bertucci, Caterina
    Shaffer, Tristan
    Hodsdon, Lauren
    Garg, Kavita
    Hosseini, Seyed Ali
    Lim, Lee
    Osmundson, Evan
    Massion, Pierre
    Lovly, Christine
    Iams, Wade
    CANCER RESEARCH, 2020, 80 (16)
  • [33] Circulating tumor cell as a predictive marker for immunotherapy in advnaced non-small cell lung cancer
    Park, Cheol-Kyu
    Yoon, Joon-Young
    Kim, Min-Suk
    Koh, Bo-Gun
    Cho, Hyun-Ju
    Oh, In-Jae
    Kim, Young-Chul
    CANCER RESEARCH, 2020, 80 (16)
  • [34] Circulating tumor cell clusters are a potential biomarker for detection of non-small cell lung cancer
    Manjunath, Yariswamy
    Upparahalli, Sathisha V.
    Suvilesh, Kanve N.
    Avella, Diego M.
    Kimchi, Eric T.
    Staveley-O'Carroll, Kevin F.
    Li, Guangfu
    Kaifi, Jussuf T.
    LUNG CANCER, 2019, 134 : 147 - 150
  • [35] Circulating cell-free tumor DNA (cfDNA) testing in small cell lung cancer.
    Morgensztern, Daniel
    Devarakonda, Siddhartha H. K.
    Masood, Ashiq
    Waqar, Saiama Naheed
    Carmack, Alicia C.
    Banks, Kimberly C.
    Lanman, Richard Burnham
    Govindan, Ramaswamy
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [36] Circulating Tumor Cell as a Predictive Marker for Immunotherapy in Advanced Non-Small Cell Lung Cancer
    Park, C.
    Oh, H.
    Kim, M.
    Kim, B.
    Cho, H.
    Oh, I.
    Kim, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S418 - S418
  • [37] Single Cell Transcriptome Atlas of circulating Tumor Cells in non-small cell Lung Cancer
    Ruff, L.
    Rieckmann, L. M.
    Spohn, M.
    Selbuz, E.
    Schubert, C.
    Agorku, D.
    Becker, L.
    Borchers, A.
    Krause, J.
    Heinemann, S.
    Kobus, F.
    Hille, J.
    Tehrany, A. L.
    Velthaus-Rusik, J. -L.
    Franzenburg, S.
    Christopoulos, P.
    Winter, H.
    Thomas, M.
    Riethdorf, S.
    Gagliani, N.
    Bokemeyer, C.
    Krebs, C. F.
    Sprick, M.
    Trumpp, A.
    Peine, S.
    Hardt, O.
    Stoecklein, N. H.
    Pantel, K.
    Rosenstiel, P.
    Loges, S.
    Janning, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 99 - 100
  • [38] The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancer
    Ross, Kirsty
    Pailler, Emma
    Faugeroux, Vincent
    Taylor, Melissa
    Oulhen, Marianne
    Auger, Nathalie
    Planchard, David
    Soria, Jean-Charles
    Lindsay, Colin R.
    Besse, Benjamin
    Vielh, Philippe
    Farace, Francoise
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2015, 15 (12) : 1605 - 1629
  • [39] A Functional Role for Tumor Cell Heterogeneity in a Mouse Model of Small Cell Lung Cancer
    Calbo, Joaquim
    van Montfort, Erwin
    Proost, Natalie
    van Drunen, Ellen
    Beverloo, H. Berna
    Meuwissen, Ralph
    Berns, Anton
    CANCER CELL, 2011, 19 (02) : 244 - 256
  • [40] Cancer Stem Cell-Like Circulating Tumor Cells Are Prognostic in Non-Small Cell Lung Cancer
    Obermayr, Eva
    Koppensteiner, Nina
    Heinzl, Nicole
    Schuster, Eva
    Holzer, Barbara
    Fabikan, Hannah
    Weinlinger, Christoph
    Illini, Oliver
    Hochmair, Maximilian
    Zeillinger, Robert
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (11):